New Assay May More Precisely Detect Allograft Rejection After Kidney Transplant

New Assay May More Precisely Detect Allograft Rejection After Kidney Transplant

A donor-derived cell-free DNA assay from Natera Inc. detected allograft rejection earlier and more precisely than other currently available tests for patients who have undergone kidney transplant, regardless of donor-recipient relationships, according to published study results.

Click here to read more.

Study Finds NeurOptics' Device Can Help Predict Cerebral Ischemia

Study Finds NeurOptics' Device Can Help Predict Cerebral Ischemia

A new study has found that NeurOptics’ NPi-200 pupillometer, which provides an automated assessment of the pupillary light reflex, may give an early warning of delayed cerebral ischemia, enabling preemptive care. The study was published in the Journal of Neurosurgery.

Click here to read more.

New Natera CEO Highlights Three Goals for Company at JP Morgan

New Natera CEO Highlights Three Goals for Company at JP Morgan

Natera plans to focus on three main goals in the coming year, according to its new CEO, Steve Chapman: expanding its leadership in reproductive health by pushing toward becoming cash-flow break-even in that business, establishing Signatera as a standard test in cancer care, and commercializing and securing reimbursement coverage for its kidney transplantation test.

Click here to read more

Stryker's 3D-Printed Tritanium Cage Shines in Study

Stryker's 3D-Printed Tritanium Cage Shines in Study

A comparison of interbody cages has resulted in the publication of new results on Allendale, New Jersey-based Stryker Spine’s 3D-printed Tritanium cages.

The pre-clinical animal study, “Bony Ingrowth Potential of 3D Printed Porous Titanium Alloy: A Direct Comparison of Interbody Cage Materials in an In Vivo Ovine Lumbar Fusion Model,” was published in the July issue of The Spine Journal.”

Click here to read more